{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:19:11Z","timestamp":1773281951091,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,5,18]],"date-time":"2012-05-18T00:00:00Z","timestamp":1337299200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1471-2415-12-9","type":"journal-article","created":{"date-parts":[[2012,5,18]],"date-time":"2012-05-18T12:14:19Z","timestamp":1337343259000},"source":"Crossref","is-referenced-by-count":15,"title":["A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125\u2009\u03bcg\/mL to latanoprost 50\u2009\u03bcg\/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension"],"prefix":"10.1186","volume":"12","author":[{"given":"David","family":"Eveleth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Starita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Tressler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,5,18]]},"reference":[{"issue":"8","key":"259_CR1","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1167\/iovs.03-1274","volume":"45","author":"JB Jonas","year":"2004","unstructured":"Jonas JB, Martus P, Horn FK, Junemann A, Korth M, Budde WM: Predictive factors of the optic nerve head for development or progression of glaucomatous visual field loss. Invest Ophthalmol Vis Sci. 2004, 45 (8): 2613-2618. 10.1167\/iovs.03-1274.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9422","key":"259_CR2","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/S0140-6736(04)16257-0","volume":"363","author":"RN Weinreb","year":"2004","unstructured":"Weinreb RN, Khaw PT: Primary open-angle glaucoma. Lancet. 2004, 363 (9422): 1711-1720. 10.1016\/S0140-6736(04)16257-0.","journal-title":"Lancet"},{"key":"259_CR3","doi-asserted-by":"crossref","unstructured":"The advanced glaucoma intervention study (AGIS): 7. the relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000, 130 (4): 429-440.","DOI":"10.1016\/S0002-9394(00)00538-9"},{"issue":"10","key":"259_CR4","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","volume":"120","author":"A Heijl","year":"2002","unstructured":"Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, for the Early Manifest Glaucoma Trial Group: Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol. 2002, 120 (10): 1268-1279.","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"259_CR5","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/archopht.120.6.701","volume":"120","author":"MA Kass","year":"2002","unstructured":"Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK, Wilson MR, Gordon MO, for the Ocular Hypertension Treatment Study Group: The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002, 120 (6): 701-713.","journal-title":"Arch Ophthalmol"},{"issue":"8","key":"259_CR6","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1007\/s00417-003-0835-1","volume":"242","author":"S Dinslage","year":"2004","unstructured":"Dinslage S, Hueber A, Diestelhorst M, Krieglstein GK: The influence of Latanoprost 0.005% on aqueous humor flow and outflow facility in glaucoma patients: a double-masked placebo-controlled clinical study. Graefes Arch Clin Exp Ophthalmol. 2004, 242 (8): 654-660. 10.1007\/s00417-003-0835-1.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"259_CR7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/00061198-200206000-00015","volume":"11","author":"CB Toris","year":"2002","unstructured":"Toris CB, Koepsell SA, Yablonski ME, Camras CB: Aqueous humor dynamics in ocular hypertensive patients. J Glaucoma. 2002, 11 (3): 253-258. 10.1097\/00061198-200206000-00015.","journal-title":"J Glaucoma"},{"issue":"5","key":"259_CR8","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.ophtha.2007.07.002","volume":"115","author":"KS Lim","year":"2008","unstructured":"Lim KS, Nau CB, O'Byrne MM, Hodge DO, Toris CB, McLaren JW, Johnson DH: Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008, 115 (5): 790-795 e794. 10.1016\/j.ophtha.2007.07.002.","journal-title":"Ophthalmology"},{"issue":"6","key":"259_CR9","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1097\/IJG.0b013e3181d12dd8","volume":"19","author":"TV Johnson","year":"2010","unstructured":"Johnson TV, Fan S, Zhan G, Camras CB, Toris CB: Efficacy and mechanisms of intraocular pressure reduction with latanoprost and timolol in participants with ocular hypertension: a comparison of 1 and 6\u2009weeks of treatment. J Glaucoma. 2010, 19 (6): 356-364. 10.1097\/IJG.0b013e3181d12dd8.","journal-title":"J Glaucoma"},{"issue":"Suppl 1","key":"259_CR10","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.1016\/j.survophthal.2008.08.010","volume":"53","author":"CB Toris","year":"2008","unstructured":"Toris CB, Gabelt BT, Kaufman PL: Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008, 53 (Suppl 1): S107-S120.","journal-title":"Surv Ophthalmol"},{"issue":"Suppl 1","key":"259_CR11","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1016\/S0039-6257(02)00306-5","volume":"47","author":"RN Weinreb","year":"2002","unstructured":"Weinreb RN, Toris CB, Gabelt BT, Lindsey JD, Kaufman PL: Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol. 2002, 47 (Suppl 1): S53-64.","journal-title":"Surv Ophthalmol"},{"issue":"Suppl 2","key":"259_CR12","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1016\/S0039-6257(97)80009-4","volume":"41","author":"CB Camras","year":"1997","unstructured":"Camras CB, Alm A: Initial clinical studies with prostaglandins and their analogues. Surv Ophthalmol. 1997, 41 (Suppl 2): S61-68.","journal-title":"Surv Ophthalmol"},{"issue":"3","key":"259_CR13","first-page":"270","volume":"37","author":"Y Hotehama","year":"1993","unstructured":"Hotehama Y, Mishima HK, Kitazawa Y, Masuda K: Ocular hypotensive effect of PhXA41 in patients with ocular hypertension or primary open-angle glaucoma. Jpn J Ophthalmol. 1993, 37 (3): 270-274.","journal-title":"Jpn J Ophthalmol"},{"issue":"9","key":"259_CR14","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/S0161-6420(93)31482-X","volume":"100","author":"A Alm","year":"1993","unstructured":"Alm A, Villumsen J, Tornquist P, Mandahl A, Airaksinen J, Tuulonen A, Marsk A, Resul B, Stjernschantz J: Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study. Ophthalmology. 1993, 100 (9): 1312-1316. discussion 1316\u20131317","journal-title":"Ophthalmology"},{"issue":"12","key":"259_CR15","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/S0161-6420(95)30798-1","volume":"102","author":"A Alm","year":"1995","unstructured":"Alm A, Stjernschantz J: Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian latanoprost study group. Ophthalmology. 1995, 102 (12): 1743-1752.","journal-title":"Ophthalmology"},{"issue":"Suppl 2","key":"259_CR16","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.1016\/S0039-6257(97)80011-2","volume":"41","author":"M Diestelhorst","year":"1997","unstructured":"Diestelhorst M, Krieglstein GK, Lusky M, Nagasubramanian S: Clinical dose-regimen studies with latanoprost, a new ocular hypotensive PGF2 alpha analogue. Surv Ophthalmol. 1997, 41 (Suppl 2): S77-81.","journal-title":"Surv Ophthalmol"},{"issue":"10","key":"259_CR17","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1136\/bjo.81.10.867","volume":"81","author":"B Fristrom","year":"1997","unstructured":"Fristrom B, Nilsson SE: A double masked comparison of the intraocular pressure reducing effect of latanoprost 0.005% and 0.001% administered once daily in open angle glaucoma and ocular hypertension. Br J Ophthalmol. 1997, 81 (10): 867-870. 10.1136\/bjo.81.10.867.","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"259_CR18","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1080\/02713689808951229","volume":"17","author":"C Linden","year":"1998","unstructured":"Linden C, Alm A: Latanoprost twice daily is less effective than once daily: indication of receptor subsensitivity?. Curr Eye Res. 1998, 17 (6): 567-572. 10.1080\/02713689808951229.","journal-title":"Curr Eye Res"},{"issue":"10","key":"259_CR19","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1136\/bjo.85.10.1163","volume":"85","author":"C Linden","year":"2001","unstructured":"Linden C, Alm A: The effect on intraocular pressure of latanoprost once or four times daily. Br J Ophthalmol. 2001, 85 (10): 1163-1166. 10.1136\/bjo.85.10.1163.","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"259_CR20","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1016\/S0161-6420(97)30074-8","volume":"104","author":"M Lusky","year":"1997","unstructured":"Lusky M, Ticho U, Glovinsky J, Weinberger D, Nesher R, Yassur Y, Melamed S: A comparative study of two dose regimens of latanoprost in patients with elevated intraocular pressure. Ophthalmology. 1997, 104 (10): 1720-1724.","journal-title":"Ophthalmology"},{"issue":"9","key":"259_CR21","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/S0161-6420(13)31817-X","volume":"100","author":"S Nagasubramanian","year":"1993","unstructured":"Nagasubramanian S, Sheth GP, Hitchings RA, Stjernschantz J: Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens. Ophthalmology. 1993, 100 (9): 1305-1311.","journal-title":"Ophthalmology"},{"issue":"1","key":"259_CR22","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0161-6420(96)30741-0","volume":"103","author":"MA Kass","year":"1996","unstructured":"Kass MA: Standardizing the measurement of intraocular pressure for clinical research. Guidelines from the eye care technology forum. Ophthalmology. 1996, 103 (1): 183-185.","journal-title":"Ophthalmology"},{"issue":"4","key":"259_CR23","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.ajo.2009.12.003","volume":"149","author":"LJ Katz","year":"2010","unstructured":"Katz LJ, Cohen JS, Batoosingh AL, Felix C, Shu V, Schiffman RM: Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension. Am J Ophthalmol. 2010, 149 (4): 661-671 e661. 10.1016\/j.ajo.2009.12.003.","journal-title":"Am J Ophthalmol"},{"issue":"Suppl 1","key":"259_CR24","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1016\/j.survophthal.2008.08.004","volume":"53","author":"A Alm","year":"2008","unstructured":"Alm A, Grierson I, Shields MB: Side effects associated with prostaglandin analog therapy. Surv Ophthalmol. 2008, 53 (Suppl 1): S93-105.","journal-title":"Surv Ophthalmol"},{"issue":"4","key":"259_CR25","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.exer.2008.08.022","volume":"88","author":"KP Cracknell","year":"2009","unstructured":"Cracknell KP, Grierson I: Prostaglandin analogues in the anterior eye: their pressure lowering action and side effects. Exp Eye Res. 2009, 88 (4): 786-791. 10.1016\/j.exer.2008.08.022.","journal-title":"Exp Eye Res"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2415-12-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2415-12-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2415-12-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2415-12-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T22:05:38Z","timestamp":1548194738000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/1471-2415-12-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,18]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["259"],"URL":"https:\/\/doi.org\/10.1186\/1471-2415-12-9","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,18]]},"article-number":"9"}}